Premium
Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal Function
Author(s) -
Gordi Toufigh,
Blackburn Brent,
Lieu Hsiao
Publication year - 2007
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270007301620
Subject(s) - regadenoson , medicine , pharmacokinetics , tolerability , renal function , creatinine , blood pressure , population , adverse effect , myocardial perfusion imaging , cardiology , pharmacology , anesthesia , perfusion , environmental health
The authors have investigated the pharmacokinetics and tolerability of regadenoson, a selective A 2A adenosine receptor agonist for use in drug‐stressed myocardial perfusion imaging in subjects with varying degrees of renal function. Sixteen subjects with different creatinine clearance values (range: 15–132 mL/min) received a single intravenous bolus dose of 400 μg regadenoson. A population pharmacokinetic model was developed to describe the pharmacokinetics of regadenoson in these subjects. Regadenoson elimination half‐life was prolonged with decreasing renal function. However, maximum plasma concentrations, number, or severity of adverse events did not differ significantly between the subjects. Heart rate increased in all subjects after regadenoson injection but returned to normal within 150 minutes. There were no blood pressure pattern differences with respect to renal function. Results from this study do not indicate that dose adjustments are necessary when subjects with decreased renal function are administered the clinically relevant dose of 400 μg regadenoson.